Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Not listed Phase 2 Interventional Accepts healthy volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

ClinicalTrials.gov ID: NCT00044226

Public ClinicalTrials.gov record NCT00044226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair your prostate or treat your BPH. Patients will first undergo a phone screening to confirm their eligibility and interest and to rule out any exclusionary history or medications. Eligible patients will be scheduled to come in to the clinic to sign an Informed Consent Form. Patients will then undergo blood and urine tests, a complete physical examination and history and answer several questionnaires to determine their eligibility. Patients will have a total of at least 7-8 visits over 20 weeks to the clinic during this study.Qualified patients receive free study medication, free medical care (physical examinations, EKG, laboratory tests) for the duration of the study.

Study identification

NCT ID
NCT00044226
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Milkhaus Laboratory
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
45 Years to 80 Years
Sex
Male
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2002
Primary completion
Not listed
Completion
Sep 30, 2002
Last update posted
Jun 23, 2005

2002

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Charles White, MD Mobile Alabama 36608 Recruiting
Douglas Young, MD Fair Oaks California 95628 Recruiting
Rodney Anderson, MD Stanford California 94305 Recruiting
Eugene Dula, MD Van Nuys California 91405 Recruiting
Joel Kaufman, MD Aurora Colorado 80012 Recruiting
Donald Bergner, MD Clearwater Florida 33761 Recruiting
Ira Klimberg, MD Ocala Florida 34474 Recruiting
Gary Friedlander, MD Rockville Maryland 20850 Recruiting
Sheldon Freedman, MD Las Vegas Nevada 89109 Recruiting
Edward Loizides, MD Bay Shore New York 11706 Recruiting
Richard Landau, MD Sellersville Pennsylvania 18960 Recruiting
H. Pat Hezmall, MD Fort Worth Texas 73104 Recruiting
Michael Godschalk, MD Richmond Virginia 23249 Recruiting
Roger Fincher, MD Spokane Washington 99202 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00044226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2005 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00044226 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →